Research Funding Opportunitieshttps://researchfunding.duke.edu/search-results?search_api_views_fulltext=translational&opportunity_external_date_2=All&opportunity_external_date_1=4/30/2019&opportunity_external_date_3=&changed_1=&changed_2=
enCongressionally Directed Medical Research Programs -- Neurotoxin Exposure Treatment Parkinson’s Program -- Synergistic Idea Awardhttps://researchfunding.duke.edu/congressionally-directed-medical-research-programs-neurotoxin-exposure-treatment-parkinson%E2%80%99s-program
<strong>Deadline:</strong> <span class="date-display-single" property="dc:date" datatype="xsd:dateTime" content="2020-08-18T00:00:00-04:00">8/18/2020</span> </br>
<strong>Funding Agency:</strong> Department of Defense</br>
<strong>Discipline:</strong>
<ul><li>Engineering and Physical Sciences</li>
<li>Environmental &amp; Life Sciences</li>
<li>Interdisciplinary</li>
<li>Medical</li>
<li>Medical - Basic Science</li>
<li>Medical - Clinical Science</li>
<li>Medical - Translational</li>
</ul>
<strong>Who's Eligible:</strong>
<ul><li>Faculty</li>
<li>Junior Faculty</li>
</ul>
<strong>Award Amount:</strong>
$3,000,000</br>
<strong>Overview:</strong>
<p>Applications to the Fiscal Year 2020 (FY20) Neurotoxin Exposure Treatment Parkinson’s (NETP) Program are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The NETP Program was initiated in FY97 to provide support for research of exceptional scientific merit leading to an understanding of the cause, prevention, and treatment of Parkinson’s disease (PD) in the context of neurotoxin exposure. Appropriations for the NETP Program from FY97 through FY18 totaled $452.75 million (M). The FY20 appropriation is $16M.</p>
<p>The vision of the NETP Program is to eliminate Parkinson’s disease through neurotoxin exposure and treatment-related research in partnership with scientists and consumers.</p>
<p>The NETP Program Synergistic Idea Award supports new ideas that represent synergistic approaches to neurotoxin exposure and treatment-related Parkinson’s disease research involving two to four Principal Investigators (PIs) at the Assistant Professor (or equivalent) level or above. These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in neurotoxin exposure and treatment-related Parkinson’s research. This award is designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields. The NETP Program seeks applications from investigators working in a wide spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research.</p>
<p>The NETP Program Synergistic Idea Award, if successful, should impact an area of paramount importance in Parkinson’s disease, in the context of neurotoxin exposure and treatment. In the context that neurotoxin exposure increases the risk for Parkinson’s disease, the application must propose neurotoxin exposure and treatment-related Parkinson’s disease research. The application must clearly and explicitly describe the potential impact of the proposed study on neurotoxin exposure-related Parkinson’s disease and convey its level of significance. The research should benefit individuals with Parkinson’s disease, by improving the understanding, prevention, diagnosis, and/or treatment of neurotoxin exposure-related Parkinson’s disease.</p>
<p>The Synergistic Idea Award requires that multiple investigators jointly design a single project, with comparable levels of intellectual input from each PI. However, each partner will be recognized as a PI, submit a separate application (even if the partners are at the same organization), and serve as the PI on an individual award. The research project must be supported by the unique expertise, experience, and abilities of each PI, and it must clearly define the synergistic components that will facilitate and accelerate progress in a way that could not be accomplished through independent efforts. Multidisciplinary projects are encouraged, and multiinstitutional projects are allowed. Each proposed study must include clearly stated plans for interactions among all PIs and organizations involved. The plans must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.</p>
<p>Deadlines:</p>
<p>• Required Pre-Application Submission Deadline: <strong>August 18, 2020 </strong></p>
<p>• Application Submission Deadline: <strong>September 16, 2020</strong></p>
May 8, 2020 - 9:14 am<strong>Funding Agency:</strong> Department of Defense</br>148,358Congressionally Directed Medical Research Programs (CDMRP) -- Peer Reviewed Cancer Research Program (PRCRP) -- Translational Team Science Awardhttps://researchfunding.duke.edu/congressionally-directed-medical-research-programs-cdmrp-peer-reviewed-cancer-research-program-prc-0
<strong>Deadline:</strong> <span class="date-display-single" property="dc:date" datatype="xsd:dateTime" content="2020-07-30T00:00:00-04:00">7/30/2020</span> </br>
<strong>Funding Agency:</strong> Department of Defense</br>
<strong>Discipline:</strong>
<ul><li>Engineering and Physical Sciences</li>
<li>Interdisciplinary</li>
<li>Medical</li>
<li>Medical - Basic Science</li>
<li>Medical - Clinical Science</li>
<li>Medical - Translational</li>
</ul>
<strong>Who's Eligible:</strong>
<ul><li>Faculty</li>
<li>Junior Faculty</li>
</ul>
<strong>Award Amount:</strong>
$1,500,000</br>
<strong>Overview:</strong>
<p>The FY20 PRCRP Translational Team Science Award (TTSA) supports hypothesis-driven translational studies. These studies should be associated with clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings.</p>
<p>The FY20 PRCRP TTSA Areas of Emphasis (strongly encouraged but not required):</p>
<p>• Interventions to improve quality of life for cancer patients and/or survivors</p>
<p>• Cancer prevention or early detection</p>
<p>Applications proposing a study not within the scope of the FY20 PRCRP TTSA Areas of Emphasis must demonstrate that the research proposed once translated to the clinic will have lasting impact in the research area studies.</p>
<p>Deadlines:<br />
• Required Pre-Application Deadline: <strong>July 30, 2020</strong><br />
• Application Submission Deadline: <strong>August 27, 2020</strong></p>
April 27, 2015 - 12:00 am<strong>Funding Agency:</strong> Department of Defense</br>140,892